BARBARA ANN KARMANOS CANCER INSTITUTE
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1995-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.karmanos.org
Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Phase 1
Completed
- Conditions
- Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 80
- Registration Number
- NCT00003174
- Locations
- 🇺🇸
Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer
Phase 2
Terminated
- Conditions
- Breast Cancer
- Interventions
- Biological: therapeutic autologous lymphocytesDrug: Ifosfamide, carboplatin, and etoposide (ICE) regimenDrug: Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)Procedure: LeukapheresisProcedure: peripheral blood stem cell transplantation (PBSCT)
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 7
- Registration Number
- NCT00020722
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma
Phase 2
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT00004024
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 34
- Registration Number
- NCT00030407
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00016185
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 36
- Registration Number
- NCT00004144
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Biological Therapy in Treating Women With Stage IV Breast Cancer
Phase 1
Completed
- Conditions
- Breast Cancer
- Interventions
- Biological: AldesleukinBiological: SargramostimBiological: therapeutic autologous lymphocytes
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 6
- Registration Number
- NCT00027807
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
© Copyright 2025. All Rights Reserved by MedPath